|
1
|
Golan A, Joosting AC and Orchard ME: Mumps
virus and ovarian cancer. S Afr Med J. 56:18–20. 1979.PubMed/NCBI
|
|
2
|
Skates SJ, Menon U, Macdonald N, Rosenthal
AN, Oram DH, Knapp RC and Jacobs IJ: Calculation of the risk of
ovarian cancer from serial CA-125 values for preclinical detection
in postmenopausal Women. J Clin Oncol. 21 (10 Suppl):206s–210s.
2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Makar AP and Tropé CG: Endometrial and
ovarian malignancies: Epidemiology, etiology and prognostic
factors. Acta Obstet Gynecol Scand. 71:331–336. 1992.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Du K, Gong HY and Gong ZM: Influence of
serum VEGF levels on therapeutic outcome and diagnosis/prognostic
value in patients with cervical cancer. Asian Pac J Cancer Prev.
15:8793–8796. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Suzuki M, Ohwara M, Sekiguchi I and Sato
I: Radical cytoreductive surgery combined with
platinums-carboplatin and cisplatin chemotherapy for advanced
ovarian cancer. Int J Gynecol Cancer. 9:54–60. 2010.
|
|
6
|
Slotman BJ and Rao BR: Ovarian cancer
(review) Etiology, diagnosis, prognosis, surgery, radiotherapy,
chemotherapy and endocrine therapy. Anticancer Res. 8:417–434.
1988.PubMed/NCBI
|
|
7
|
Tu H, Huang H, Huang QD, Li Z, Feng YL and
Liu JH: Treatment and prognostic analysis of ovarian cancer
patients with isolated region of lymph node recurrence. Zhonghua Fu
Chan Ke Za Zhi. 47:928–933. 2012.PubMed/NCBI(In Chinese).
|
|
8
|
Vance KW and Ponting CP: Transcriptional
regulatory functions of nuclear long noncoding RNAs. Trends Genet.
30:348–355. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li Y, Zhang J, Huo C, Ding N, Li J, Xiao
J, Lin X, Cai B, Zhang Y and Xu J: Dynamic organization of lncRNA
and Circular RNA regulators collectively controlled cardiac
differentiation in humans. Ebiomedicine. 24:137–146.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao
T, Liu Y, Ou J, Wang D, Yao L, et al: LncRNA-HOST2 regulates cell
biological behaviors in epithelial ovarian cancer through a
mechanism involving microRNA let-7b. Hum Mol Genet. 24:841–852.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chai Y, Liu J, Zhang Z and Liu L:
HuR-regulated lncRNA NEAT1 stability in tumorigenesis and
progression of ovarian cancer. Cancer Med. 5:1588–1598.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Liu E, Liu Z and Zhou Y:
Carboplatin-docetaxel-induced activity against ovarian cancer is
dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol.
8:3803–3810. 2015.PubMed/NCBI
|
|
13
|
Rong L, Zhao R and Lu J: Highly expressed
long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer
progression via Wnt/β-catenin signaling. Biochem Biophys Res
Commun. 484:586–591. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang X, Duan B and Zhou X: Long non-coding
RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by
regulating EMT and Notch signaling pathway. Eur Rev Med Pharmacol
Sci. 21:3586–3591. 2017.PubMed/NCBI
|
|
15
|
Bao J, Zhou C, Zhang J, Mo J, Ye Q, He J
and Diao J: Upregulation of the long noncoding RNA FOXD2-AS1
predicts poor prognosis in esophageal squamous cell carcinoma.
Cancer Biomark. 21:527–533. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boo L, Ho WY, Ali NM, Yeap SK, Ky H, Chan
KG, Yin WF, Satharasinghe DA, Liew WC, Tan SW, et al: MiRNA
transcriptome profiling of spheroid-enriched cells with cancer stem
cell properties in human breast MCF-7 cell line. Int J Biol Sci.
12:427–445. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Egaña-Gorroño L, Guardo AC, Bargalló ME,
Planet E, Vilaplana E, Escribà T, Pérez I, Gatell JM, García F,
Arnedo M, et al: MicroRNA profile in CD8+ T-lymphocytes from
HIV-infected individuals: Relationship with antiviral immune
response and disease progression. PLoS One.
11(e0155245)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang A, Jin C, Li H, Qin Q and Li L:
LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by
targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol.
120:1705–1713. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yan H, Li H, Li P, Li X, Lin J, Zhu L,
Silva MA, Wang X, Wang P and Zhang Z: Long noncoding RNA MLK7-AS1
promotes ovarian cancer cells progression by modulating
miR-375/YAP1 axis. J Exp Clin Cancer Res. 37(237)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Soegaard M, Kjaer SK, Cox M, Wozniak E,
Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA and Ramus
SJ: BRCA1 and BRCA2 mutation prevalence and clinical
characteristics of a population-based series of ovarian cancer
cases from Denmark. Clin Cancer Res. 14:3761–3767. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kozak KR, Amneus MW, Pusey SM, Su F, Luong
MN, Luong SA, Reddy ST and Farias-Eisner R: Identification of
biomarkers for ovarian cancer using strong anion-exchange
ProteinChips: Potential use in diagnosis and prognosis. Proc Natl
Acad Sci USA. 100:12343–12348. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tsai MC, Spitale RC and Chang HY: Long
intergenic noncoding RNAs: New links in cancer progression. Cancer
Res. 71:3–7. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang B, Liu M, Zhuang R, Jiang J, Gao J,
Wang H, Chen H, Zhang Z, Kuang Y and Li P: Long non-coding RNA
CCAT2 promotes epithelial-mesenchymal transition involving
Wnt/β-catenin pathway in epithelial ovarian carcinoma cells. Oncol
Lett. 15:3369–3375. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Usongo M, Li X and Farookhi R: Activation
of the canonical WNT signaling pathway promotes ovarian surface
epithelial proliferation without inducing β-catenin/Tcf-mediated
reporter expression. Dev Dyn. 242:291–300. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
An Q, Zhou L and Xu N: Long noncoding RNA
FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer
by sponging miR-143. Biomed Pharmacother. 103:415–420.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang L, He J, Xu H, Xu L and Li N: MiR-143
targets CTGF and exerts tumor-suppressing functions in epithelial
ovarian cancer. Am J Transl Res. 8:2716–2726. 2016.PubMed/NCBI
|
|
28
|
Chen G, Sun W, Hua X, Zeng W and Yang L:
Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma
carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene.
645:76–84. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H
and Cui Z: S100A1 promotes cell proliferation and migration and is
associated with lymph node metastasis in ovarian cancer. Discov
Med. 23:235–245. 2017.PubMed/NCBI
|
|
30
|
Xun M, Ma CF, Du QL, Ji YH and Xu JR:
Differential expression of miRNAs in enterovirus 71-infected cells.
Virol J. 12(56)2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gavalas NG, Karadimou A, Dimopoulos MA and
Bamias A: Immune response in ovarian cancer: How is the immune
system involved in prognosis and therapy: Potential for treatment
utilization. Clin Dev Immunol. 2010(791603)2011.PubMed/NCBI View Article : Google Scholar
|
